Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Recruiting Trials

In this section

tuberculosis

TB043 Tuberculosis Study – A BCG challenge study in healthy adults to help develop TB vaccines.  If you are aged 18-50, in good health, and have never received the BCG vaccine, you may be eligible to participate.  The study involves 9-11 visits over a period of around 6 months. Participants will be reimbursed for their time and travel from £705 to £750. Click here for more information.

COVID-19 Vaccine development

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers aged 18-55 years old. The study is open to participants who are based in the Thames Valley area. 

If you are interested in taking part in the trial, please find out more details and register on this website: https://covid19vaccinetrial.web.ox.ac.uk. 

 A team from the Jenner Institute and Oxford Vaccine Group, led by Prof. Sarah Gilbert, Prof. Andrew Pollard, Prof. Teresa Lambe, Dr Sandy Douglas and Prof. Adrian Hill, started work designing a vaccine on Saturday 10th January 2020. COVID-19 is a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 was first detected in the city of Wuhan, China, in December 2019, after a cluster of patients with pneumonia of unknown cause were reported to the World Health Organization (WHO).

The outbreak was declared a public health emergency of international concern on 30th January 2020, and the disease caused by SARS-CoV-2 was officially named COVID-19 on 11th February 2020. After assessing the outbreak and following transmission of the virus in many other countries worldwide, on 11th March 2020 the WHO declared COVID-19 a pandemic. This means that the disease has spread worldwide, and it is the first time that a coronavirus has led to a pandemic.

A chimpanzee adenovirus vaccine vector (ChAdOx1), developed at Oxford’s Jenner Institute, was chosen as the most suitable vaccine technology for a SARS-CoV-2 vaccine as it can generate a strong immune response from one dose and it is not a replicating virus, so it cannot cause an ongoing infection in the vaccinated individual. This also makes it safer to give to children, the elderly and anyone with a pre-existing condition such as diabetes. Chimpanzee adenoviral vectors are a very well-studied vaccine type, having been used safely in thousands of subjects, from 1 week to 90 years of age, in vaccines targeting over 10 different diseases. At the same time as preparing for and conducting the first clinical trial, production of the vaccine is being scaled up ready for larger trials, and potentially, future deployment.

Coronaviruses have club-shaped spikes on their outer coats. Immune responses from other coronavirus studies suggest that these are a good target for a vaccine. The Oxford vaccine contains the genetic sequence of this surface spike protein inside the ChAdOx1 construct. After vaccination, the surface spike protein of the coronavirus is produced, which primes the immune system to attack the coronavirus if it later infects the body. Prof. Gilbert and team have previously developed a vaccine for another human coronavirus disease, which is Middle East Respiratory Syndrome (MERS), and this has shown promise in early clinical trials. 

Would you like to keep up to date with trials?

If you would like to register with us to receive our monthly email newsletter detailing our latest trials looking for volunteers, please click here.